Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
Want to see ALNY full AI Analyst Report?
Top Page
Alnylam Pharma
(NASDAQ:ALNY)
Select Model
Select Model
Rating:63Neutral
Price Target:
$330.00
▲(6.57% Upside)
Action:ReiteratedDate:05/01/26
The score is driven primarily by improving fundamentals and a positive earnings-call outlook (record product revenue, reiterated guidance, and strong cash generation). Offsetting these are weak technicals (below major moving averages with negative MACD) and a very expensive valuation (P/E 166), which raise near-term risk and reduce upside cushion.
Positive Factors
Commercial scale & TTR franchise momentum
Alnylam has reached commercial scale with quarterly product revenues above $1B and rapid TTR franchise growth. Durable prescriber expansion, high adherence and broad payer access underpin recurring demand for flagship RNAi therapies, supporting sustained revenue run-rate and market leadership in ATTR-CM.
Negative Factors
Rising royalty pressure on margins
Increasing average royalty rates on AMVUTTRA as sales scale and periodic royalty resets create a structural headwind to product gross margins. Sustained higher royalty expense will compress long‑term gross margins and reduce the cash conversion and operating leverage from core product growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial scale & TTR franchise momentum
Alnylam has reached commercial scale with quarterly product revenues above $1B and rapid TTR franchise growth. Durable prescriber expansion, high adherence and broad payer access underpin recurring demand for flagship RNAi therapies, supporting sustained revenue run-rate and market leadership in ATTR-CM.
Read all positive factors
Alnylam Pharma (ALNY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$39.39B
Dividend YieldN/A
Average Volume (3M)1.10M
Price to Earnings (P/E)53.4
Beta (1Y)0.89
Revenue Growth82.57%
EPS GrowthN/A
CountryUS
Employees2,230
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)4.36
Shares Outstanding133,512,570
10 Day Avg. Volume1,088,688
30 Day Avg. Volume1,098,645
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)66.01
Price to Sales (P/S)14.03
P/FCF Ratio111.94
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue9.09
Enterprise Value/Gross Profit11.23
Enterprise Value/Ebitda63.49
Forecast
1Y Price Target
$449.12Price Target Upside45.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)7.24
Revenue Forecast (FY)$5.62B
Alnylam Pharma Business Overview & Revenue Model
Company Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on g...
How the Company Makes Money
Alnylam primarily makes money through (1) product sales of its commercialized RNAi therapeutics and (2) collaboration and licensing-related revenue from partnerships.
1) Product (net) revenue: The company generates revenue from selling its approv...
Alnylam Pharma Key Performance Indicators (KPIs)
Any
Revenue by Segment
Analyzes income from different business areas, highlighting which segments drive growth and profitability, and indicating strategic focus areas.
Analyzes income from different business areas, highlighting which segments drive growth and profitability, and indicating strategic focus areas.
Data provided by:
The Fly
The FlyAlnylam Pharma Earnings Call Summary
Earnings Call Date:Apr 30, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Positive
The call presented a strong commercial and financial quarter highlighted by record product revenues, robust TTR franchise growth, profitability and substantial pipeline progress including accelerated Phase III enrollment and supportive real-world evidence. Challenges noted were margin pressure from rising royalties, higher R&D/SG&A investments, an expected Germany pricing adjustment that transiently impacted international results, and typical seasonal/operational phasing headwinds. Management reiterated full-year guidance and communicated confidence in ongoing launch dynamics and pipeline execution, while acknowledging competitive and timing uncertainties.Positive Updates
Record Quarterly Product Revenues
Combined net product revenues of $1.036 billion in Q1 2026 — the company's first quarter exceeding $1 billion; +121% year-over-year and +4% sequentially versus Q4 2025.
Negative Updates
Gross Margin Pressure from Royalties
Gross margin on product sales was 80% in Q1 2026, a 5 percentage-point decrease versus Q1 2025. Decline driven by increased average royalty rates payable to Sanofi on AMVUTTRA as sales grow and an annual royalty-rate reset, with expectation of continued margin pressure as sales ramp.
Read all updates
Q1-2026 Updates
Positive
Negative
Record Quarterly Product Revenues
Combined net product revenues of $1.036 billion in Q1 2026 — the company's first quarter exceeding $1 billion; +121% year-over-year and +4% sequentially versus Q4 2025.
Read all positive updates
Company Guidance
Alnylam reiterated its full‑year 2026 guidance, reiterating $4.4–$4.7 billion in TTR product sales and noting it expects significantly higher quarter‑over‑quarter TTR revenue growth for the balance of the year to reach that range; Q1 provides the starting base with combined net product revenues of $1.036 billion (first quarter in company history >$1B), TTR net revenues of $910 million (up 153% YoY and 6% QoQ), rare disease revenue of $126 million (up 15% YoY), collaboration revenue of $82 million (down 17% YoY), and royalty revenue of $49 million (up 85% YoY). Financials also showed an 80% gross margin on product sales (down 5% YoY) with the company warning average royalties to Sanofi on AMVUTTRA will rise as sales grow (pressuring margins), non‑GAAP R&D of $335 million (up 39% YoY), non‑GAAP SG&A of $283 million (up 36% YoY), non‑GAAP operating income of $339 million (>4x YoY), and cash, cash equivalents and marketable securities of $3.0 billion (vs. $2.9 billion at 12/31/25); management also cited a modest Q1 selling‑week timing headwind (12 Wednesdays vs 14 in Q4) that it expects will normalize across upcoming quarters.Alnylam Pharma Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
55
Neutral
Cash Flow
82
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.29B | 3.71B | 2.25B | 1.83B | 1.04B | 844.29M |
| Gross Profit | 3.47B | 3.04B | 1.92B | 1.52B | 868.60M | 704.14M |
| EBITDA | 613.59M | 557.24M | -178.85M | -258.24M | -926.56M | -661.56M |
| Net Income | 577.22M | 313.75M | -278.16M | -440.24M | -1.13B | -852.82M |
Balance Sheet | ||||||
| Total Assets | 5.13B | 4.97B | 4.24B | 3.83B | 3.55B | 3.64B |
| Cash, Cash Equivalents and Short-Term Investments | 3.01B | 2.91B | 2.69B | 2.44B | 2.19B | 2.44B |
| Total Debt | 1.27B | 1.28B | 2.74B | 1.31B | 1.32B | 997.59M |
| Total Liabilities | 4.05B | 4.18B | 4.17B | 4.05B | 3.70B | 3.06B |
| Stockholders Equity | 1.08B | 789.18M | 67.09M | -220.64M | -158.22M | 588.20M |
Cash Flow | ||||||
| Free Cash Flow | 641.34M | 465.38M | -42.59M | 41.95M | -613.33M | -718.07M |
| Operating Cash Flow | 712.90M | 524.08M | -8.31M | 104.16M | -541.27M | -641.69M |
| Investing Cash Flow | 297.02M | 436.33M | -116.84M | -336.35M | 169.35M | -273.30M |
| Financing Cash Flow | -333.56M | -305.19M | 294.16M | 172.13M | 425.75M | 1.25B |
Alnylam Pharma Technical Analysis
Negative
309.66
Price Trends
323.37
Negative
360.07
Negative
393.62
Negative
Market Momentum
-0.42
Positive
42.19
Neutral
32.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALNY, the sentiment is Negative. The current price of 309.66 is below the 20-day moving average (MA) of 322.59, below the 50-day MA of 323.37, and below the 200-day MA of 393.62, indicating a bearish trend. The MACD of -0.42 indicates Positive momentum. The RSI at 42.19 is Neutral, neither overbought nor oversold. The STOCH value of 32.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALNY.
Alnylam Pharma Risk Analysis
Alnylam Pharma disclosed 46 risk factors in its most recent earnings report. Alnylam Pharma reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Alnylam Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $19.69B | 15.46 | 29.31% | ― | 21.48% | 1853.63% | |
76 Outperform | $109.09B | 27.50 | 23.93% | ― | 11.75% | ― | |
75 Outperform | $48.95B | 14.76 | 16.82% | ― | 90.23% | 51.88% | |
66 Neutral | $15.46B | 153.52 | 18.99% | ― | 19.49% | -11.88% | |
63 Neutral | $39.39B | 53.36 | 98.29% | ― | 82.57% | ― | |
55 Neutral | $23.80B | -8.99 | -6.03% | ― | 10.01% | -71.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
ALNY
Alnylam Pharma
295.05
24.86
9.20%
INCY
Incyte
98.56
37.71
61.97%
VRTX
Vertex Pharmaceuticals
429.82
-9.55
-2.17%
ARGX
Argenx Se
782.17
221.27
39.45%
GMAB
Genmab
26.43
6.50
32.61%
BNTX
BioNTech SE
94.13
-3.14
-3.23%
Alnylam Pharma Corporate Events
Business Operations and StrategyExecutive/Board Changes
Alnylam Grants CEO New Performance-Based Equity Award
Positive
Mar 4, 2026
Effective March 2, 2026, Alnylam’s board granted CEO Yvonne Greenstreet a special, fully performance-based equity award designed to retain and incentivize her as the company pursues its new “Alnylam 2030” five-year goals, after s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.